Exclusive Online Content

EXCLUSIVE ONLINE CONTENT

6/23/2022

Silo Pharma Expands License Agreement & Patent Portfolio

Silo Pharma, Inc. recently announced that it has expanded its Commercial Evaluation License Agreement (CELA) with the University of Maryland Baltimore (UMB) for its next generation Liposomal Peptide targeting….

6/22/2022

Pasithea Therapeutics Acquires Alpha-5 Integrin, LLC

Pasithea Therapeutics Corp. recently announced its acquisition of Alpha-5 integrin, LLC, a privately-held preclinical-stage company developing a monoclonal antibody (mAbs) for the treatment of amyotrophic lateral sclerosis (ALS) and….